Terumo Responds to the Novel Coronavirus Outbreak in China
TOKYO, JAPAN – February 4, 2020 – Terumo Corporation (TSE: 4543) today shared the latest information on its business operation and response in China, regarding the current outbreak of the novel coronavirus (2019-nCoV).
In China, Terumo currently has19 business locations (including 3 factories), in cities such as Beijing and Shanghai. As of February 4, there are no reports of Terumo Associates affected by the outbreak. To prevent further widespread and to protect the safety of associates, the company has requested associates to take prolonged vacation or to work from home. The Hong Kong and Taiwan office has resumed business from the end of January, and the factory in Hangzhou (Zhejiang Province) has resumed production from February 3; due to the healthcare company’s social responsibility to provide resources needed to sustain basic medical care.
Also, Terumo has provided emergency relief supplies of 2,500 thermometers and 1,250 sphygmomanometers on February 2. The products were delivered by Terumo China Holdings to the two newly built hospitals in Wuhan (Huoshenshan Hospital and Leishenshan Hospital). Terumo also intends on providing extra-corporeal membrane oxygenation (ECMO) systems used for the treatment of severe pneumonia.
Based on its Group Mission of “Contributing to Society through Healthcare,” Terumo will further strive to be of value to society at large.
About Terumo
Terumo (TSE:4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide, to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese excellent thermometer manufacturer, and has developed many first products in the world or in Japan to bolster medical infrastructure. Now its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.
###